Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile by GlobalData

VIEWS: 0 PAGES: 26

Sorrento Therapeutics, Inc. (STI) is a biopharmaceutical company, based in the US. The company discovers and develops human therapeutic antibodies to treat disease conditions such as, cancer, metabolic disease, inflammation and infectious disease. It develops therapeutic antibodies using proprietary technology platform. STI’s technology applies RNA transcription for amplification of human immunoglobin variable domain sequences. The company has entered into a discovery and development collaboration agreement with The Scripps Research Institute for prevention and treatment of MRSA Infections. It is publically treated in Over the Counter market. STI is headquartered in San Diego, California, the US.

More Info
									          Sorrento Therapeutics, Inc. (SRNE) - Pharmaceuticals & Healthcare - Deals
                                     and Alliances Profile
       Reference Code: GDPH185554D                                                                                                             Publication Date: MAR 2013

      Company Overview                                                                                        Key Facts
      Sorrento Therapeutics, Inc. (STI) is a biopharmaceutical company, based in the US.
                                                                                                              Sorrento Therapeutics, Inc., Pharmaceuticals &
      The company discovers and develops human therapeutic antibodies to treat disease
                                                                                                              Healthcare, Key Facts, 2011
      conditions such as, cancer, metabolic disease, inflammation and infectious disease.
      It develops therapeutic antibodies using proprietary technology platform. STI’s                          Web Address                           www.sorrentotherapeuti
      technology applies RNA transcription for amplification of human immunoglobin                                                                   cs.com
      variable domain sequences. The company has entered into a discovery and
                                                                                                               Revenue (US$ million)                                       0.53
      development collaboration agreement with The Scripps Research Institute for
      prevention and treatment of MRSA Infections. It is publically treated in Over the                        Number of Employees                                          13
      Counter market.                                                                                          GlobalData

      Financial Deals Landscape
        Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare,                        Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare,
        Deals by Type, 2007 to YTD 2013                                                   Deals By Year, 2007 to YTD 2013


                                                                                                                                  2                                  2
                                                                                                          2

                                                                                           No. of Deals
                                                                                                                                           1         1
                                                                                                          1


                                                                                                                 0         0                              0
                                                                                                          0
                                                                                                               2007       2008   2009     2010   2011    2012       YTD
                                                                                                                                                                    2013


                                                                                          Note: Deals include all announced pharmaceuticals & healthcare deals
         Note: Deals include all announced pharmaceuticals & healthcare deals from
                                                                                          from 2006 onwards, GlobalData
         2006 onwards, GlobalData


         Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare,                       Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare,
         Deals By Region, 2007 to YTD 2013                                                Deals By Therapy Area, 2007 to YTD 2013

                         8
                               6                                                                                      3               3
          No. of Deals




                         6                                                                                3
                                                                                           No. of Deals




                         4                                                                                                                       2              2
                                        1         1        1         1                                    2
                         2
                         0
                             North    Asia-     Europe   Middle   South                                   1
                             Americ   Pacific             East     and
                               a                          and     Central
                                                         Africa   Americ                                  0
                                                                    a                                            Infectiou Oncology Immunol Metabolic
                                                                                                                 s Disease            ogy   D isord …


         Note: Deals include all announced pharmaceuticals & healthcare deals
         from 2006 onwards, GlobalData                                                    Note: Deals include all announced pharmaceuticals & healthcare deals
                                                                                          from 2006 onwards, GlobalData




Sorrento Therapeutics, Inc. - Pharmaceuticals & Healthcare -                                                                                     Reference Code: GDPH185554D
Deals and Alliances Profile
Source : www.globalcompanyintelligence.com                                                                                                                                        Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ...................................................... 4
       Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2007 to YTD 2013 ....................................................... 5
       Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2007 to YTD 2013................................................... 6
       Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2007 to YTD 2013 ........................................ 7
       Sorrento Therapeutics, Inc., Medical Devices Deals, 2007 to YTD 2013 ........................................................................................... 8
       Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2007 to YTD 2013 .................................................... 9
       Sorrento Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details ....................................................................................... 10
          Asset Purchase............................................................................................................................................................................. 10
             Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins............................................ 10
          Partnerships.................................................................................................................................................................................. 11
             Sorrento Therapeutics Enters Into Co-Development Agreement With The Scripps Research Institute .................................... 11
          Equity Offering .............................................................................................................................................................................. 12
             Sorrento Therapeutics Completes Private Placement Of Shares For $2 Million ....................................................................... 12
          Acquisition .................................................................................................................................................................................... 13
             Sorrento Therapeutics Enters Into Option To Acquire IgDraSol ................................................................................................ 13
             Sorrento Therapeutics Completes Reverse Acquisition With QuikByte Software ..................................................................... 15
             Sorrento Therapeutics Receives Investment Of $2.3 Million From OPKO Health ..................................................................... 16
       Sorrento Therapeutics, Inc. - Key Competitors................................................................................................................................. 17
       Key Employees ................................................................................................................................................................................ 18
       Locations And Subsidiaries .............................................................................................................................................................. 19
          Head Office ................................................................................................................................................................................... 19
       Recent Developments ...................................................................................................................................................................... 20
          Financial Announcements............................................................................................................................................................. 20
             Nov 08, 2012: Sorrento Therapeutics Reports Q3 2012 Results .............................................................................................. 20
             Aug 14, 2012: Sorrento Therapeutics Reports Q2 2012 Results .............................................................................................. 21
             May 15, 2012: Sorrento Therapeutics Reports Q1 2012 Results .............
								
To top